Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 1
1974 1
1975 3
1976 1
1977 1
1980 1
1981 2
1982 1
1983 5
1984 1
1985 5
1986 8
1987 4
1988 2
1989 9
1990 8
1991 6
1992 9
1993 8
1994 14
1995 6
1996 8
1997 9
1998 17
1999 18
2000 16
2001 14
2002 10
2003 18
2004 18
2005 12
2006 18
2007 10
2008 11
2009 26
2010 19
2011 30
2012 31
2013 41
2014 50
2015 48
2016 35
2017 41
2018 42
2019 54
2020 52
2021 49
2022 53
2023 44
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

805 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Cardiomyopathy, mitochondrial"
Page 1
Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus.
Nakamura K, Miyoshi T, Yoshida M, Akagi S, Saito Y, Ejiri K, Matsuo N, Ichikawa K, Iwasaki K, Naito T, Namba Y, Yoshida M, Sugiyama H, Ito H. Nakamura K, et al. Int J Mol Sci. 2022 Mar 25;23(7):3587. doi: 10.3390/ijms23073587. Int J Mol Sci. 2022. PMID: 35408946 Free PMC article. Review.
Cardiac dysfunction in the absence of coronary artery disease, hypertension, and valvular disease is called diabetic cardiomyopathy. Diabetes-induced hyperglycemia and hyperinsulinemia lead to capillary damage, myocardial fibrosis, and myocardial hypertrophy with mitoch …
Cardiac dysfunction in the absence of coronary artery disease, hypertension, and valvular disease is called diabetic cardiomyopathy. …
Mitochondrial cardiomyopathy: pathophysiology, diagnosis, and management.
Meyers DE, Basha HI, Koenig MK. Meyers DE, et al. Tex Heart Inst J. 2013;40(4):385-94. Tex Heart Inst J. 2013. PMID: 24082366 Free PMC article. Review.
Mitochondrial disease is a heterogeneous group of multisystemic diseases that develop consequent to mutations in nuclear or mitochondrial DNA. ...In this review, we describe the complex pathophysiology of mitochondrial disease and its clinical features. We fo …
Mitochondrial disease is a heterogeneous group of multisystemic diseases that develop consequent to mutations in nuclear or mitoch …
Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy.
Jia G, DeMarco VG, Sowers JR. Jia G, et al. Nat Rev Endocrinol. 2016 Mar;12(3):144-53. doi: 10.1038/nrendo.2015.216. Epub 2015 Dec 18. Nat Rev Endocrinol. 2016. PMID: 26678809 Free PMC article. Review.
Termed diabetic cardiomyopathy, this form of cardiomyopathy is a major cause of morbidity and mortality in developed nations, and the prevalence of this condition is rising in parallel with increases in the incidence of obesity and type 2 diabetes mellitus. Of note, …
Termed diabetic cardiomyopathy, this form of cardiomyopathy is a major cause of morbidity and mortality in developed nations, …
Cardiac lipid metabolism, mitochondrial function, and heart failure.
Da Dalt L, Cabodevilla AG, Goldberg IJ, Norata GD. Da Dalt L, et al. Cardiovasc Res. 2023 Aug 19;119(10):1905-1914. doi: 10.1093/cvr/cvad100. Cardiovasc Res. 2023. PMID: 37392421 Review.
This highly energy-demanding muscle normally oxidizes almost all the available substrates to generate energy, with fatty acids being the preferred source under physiological conditions. In patients with cardiomyopathies and heart failure, changes in the main energetic subs …
This highly energy-demanding muscle normally oxidizes almost all the available substrates to generate energy, with fatty acids being the pre …
Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy.
Dhingra R, Rabinovich-Nikitin I, Rothman S, Guberman M, Gang H, Margulets V, Jassal DS, Alagarsamy KN, Dhingra S, Valenzuela Ripoll C, Billia F, Diwan A, Javaheri A, Kirshenbaum LA. Dhingra R, et al. Circulation. 2022 Sep 20;146(12):934-954. doi: 10.1161/CIRCULATIONAHA.121.058411. Epub 2022 Aug 19. Circulation. 2022. PMID: 35983756 Free PMC article.
METHODS: Using a combination of in vivo (4 weekly injections of DOX 5 mg.kg(-1).wk(-1)) in C57/BL6J mice and in vitro approaches (rat, mouse, and human inducible pluripotent stem cell-derived cardiac myocytes), we monitored TNFalpha levels, lactate dehydrogenase, cardiac ultrastr …
METHODS: Using a combination of in vivo (4 weekly injections of DOX 5 mg.kg(-1).wk(-1)) in C57/BL6J mice and in vitro approaches (rat, mouse …
Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy.
Knapp M, Tu X, Wu R. Knapp M, et al. Acta Pharmacol Sin. 2019 Jan;40(1):1-8. doi: 10.1038/s41401-018-0042-6. Epub 2018 Jun 4. Acta Pharmacol Sin. 2019. PMID: 29867137 Free PMC article. Review.
This diabetes-associated clinical entity is considered a distinct disease process referred to as "diabetic cardiomyopathy". However, it is not clear how diabetes promotes cardiac dysfunction. ...The current review provides an update on mechanisms that specifically target e …
This diabetes-associated clinical entity is considered a distinct disease process referred to as "diabetic cardiomyopathy". However, …
FGF1(deltaHBS) prevents diabetic cardiomyopathy by maintaining mitochondrial homeostasis and reducing oxidative stress via AMPK/Nur77 suppression.
Wang D, Yin Y, Wang S, Zhao T, Gong F, Zhao Y, Wang B, Huang Y, Cheng Z, Zhu G, Wang Z, Wang Y, Ren J, Liang G, Li X, Huang Z. Wang D, et al. Signal Transduct Target Ther. 2021 Mar 24;6(1):133. doi: 10.1038/s41392-021-00542-2. Signal Transduct Target Ther. 2021. PMID: 33762571 Free PMC article.
Here, we show that serum levels of FGF1 were decreased and positively correlated with fraction shortening in diabetic cardiomyopathy (DCM) patients, indicating that FGF1 is a potential therapeutic target for DCM. ...Both in vivo and in vitro studies indicate that FGF1(HBS) …
Here, we show that serum levels of FGF1 were decreased and positively correlated with fraction shortening in diabetic cardiomyopathy …
Mitochondrial Telomerase Reverse Transcriptase Protects From Myocardial Ischemia/Reperfusion Injury by Improving Complex I Composition and Function.
Ale-Agha N, Jakobs P, Goy C, Zurek M, Rosen J, Dyballa-Rukes N, Metzger S, Greulich J, von Ameln F, Eckermann O, Unfried K, Brack F, Grandoch M, Thielmann M, Kamler M, Gedik N, Kleinbongard P, Heinen A, Heusch G, Gödecke A, Altschmied J, Haendeler J. Ale-Agha N, et al. Circulation. 2021 Dec 7;144(23):1876-1890. doi: 10.1161/CIRCULATIONAHA.120.051923. Epub 2021 Oct 21. Circulation. 2021. PMID: 34672678 Free article.
BACKGROUND: The catalytic subunit of telomerase, telomerase reverse transcriptase (TERT), has protective functions in the cardiovascular system. TERT is not only present in the nucleus but also in mitochondria. However, it is unclear whether nuclear or mitochondrial …
BACKGROUND: The catalytic subunit of telomerase, telomerase reverse transcriptase (TERT), has protective functions in the cardiovascular sys …
New insights into the role of mitochondrial metabolic dysregulation and immune infiltration in septic cardiomyopathy by integrated bioinformatics analysis and experimental validation.
Li Y, Yu J, Li R, Zhou H, Chang X. Li Y, et al. Cell Mol Biol Lett. 2024 Jan 30;29(1):21. doi: 10.1186/s11658-024-00536-2. Cell Mol Biol Lett. 2024. PMID: 38291374 Free PMC article.
In vivo and in vitro experiments were performed to validate the pathogenetic mechanism of SCM and the therapeutic efficacy of candidate drugs. RESULTS: Six hub mitochondria-related DEGs [MitoDEGs; translocase of inner mitochondrial membrane domain-containing 1 (TIMM …
In vivo and in vitro experiments were performed to validate the pathogenetic mechanism of SCM and the therapeutic efficacy of candidate drug …
FAM210A regulates mitochondrial translation and maintains cardiac mitochondrial homeostasis.
Wu J, Subbaiah KCV, Hedaya O, Chen S, Munger J, Tang WHW, Yan C, Yao P. Wu J, et al. Cardiovasc Res. 2023 Nov 15;119(14):2441-2457. doi: 10.1093/cvr/cvad124. Cardiovasc Res. 2023. PMID: 37522353
Fam210a deficient cardiomyocytes exhibit severe mitochondrial morphological disruption and functional decline accompanied by myofilament disarray at the late stage of cardiomyopathy. Furthermore, we observed increased mitochondrial reactive oxygen spec …
Fam210a deficient cardiomyocytes exhibit severe mitochondrial morphological disruption and functional decline accompanied by myofilam …
805 results